Adaptive Biotechnologies Corpor

Filing receipts

“26 Adaptive Biotechnologies Corporation The following is a reconciliation of net loss attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA for the periods presented (in thousands): Three Months Ended March 31, 2026 2025 Net loss attributable to Adaptive Biotechnologies Corporation $ (20,033 ) $ (29,852 ) Interest and other income, net (2,080 ) (2,679 ) Interest expense (1) 2,889 2,905 Depreciation and amortization expense 3,837 4,731 Impairment of long-lived assets (2) 347 — Restructuring expense (2) 643 — Share-based compensation expense (3) 11,928 12,147 Adjusted EBITDA $ (2,469 ) $ (12,748 ) (1) Represents costs ass...”

“Other limitations include that Adjusted EBITDA, including segment Adjusted EBITDA, does not reflect: • all expenditures or future requirements for capital expenditures or contractual commitments; • changes in our working capital needs; • interest expense, which is an ongoing element of our costs to operate; • income tax (expense) benefit, which may be a necessary element of our costs and ability to operate; • the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future; • the noncash component of employee compensation expense; • long-lived assets impairment costs; and • the impact of earnings or charges resulting from matters we consi...”

“The $4.9 million decrease in Immune Medicine revenue was primarily due to a $3.6 million decrease in revenue generated from the Genentech Agreement, resulting from the termination of the Genentech Agreement in August 2025, and a $1.3 million decrease in sample testing revenue generated from our biopharmaceutical and academic customers.”